Ballard Spahr represented Array BioPharma Inc. (Nasdaq: ARRY), in the recent closing of a public offering by the biopharmaceutical company, which generated total gross proceeds of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
